Rigel Pharmaceuticals Inc (RIGL)
Rigel Announces U.S. FDA Approval of REZLIDHIA™(olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Rigel Announces U.S. FDA Approval of REZLIDHIA™(olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
There are no comments here yet...